Allscripts Healthcare Solutions, Inc. (MDRX) EPS Estimated At $0.13; Profile of 3 Analysts Covering Tesco PLC (TSCDY)
April 17, 2018 - By Winifred Garcia
Among 5 analysts covering Tesco PLC (OTCMKTS:TSCDY), 3 have Buy rating, 1 Sell and 1 Hold. Therefore 60% are positive. Tesco PLC had 6 analyst reports since November 17, 2015 according to SRatingsIntel. The company was upgraded on Tuesday, November 17 by Citigroup. The rating was initiated by UBS on Friday, April 7 with “Buy”. The firm has “Underperform” rating by BNP Paribas given on Friday, January 20. The stock has “Buy” rating by HSBC on Monday, November 14. The company was downgraded on Thursday, October 6 by BNP Paribas. Kepler Cheuvreux initiated the shares of TSCDY in report on Tuesday, January 17 with “Hold” rating. See Tesco PLC (OTCMKTS:TSCDY) latest ratings:
Analysts expect Allscripts Healthcare Solutions, Inc. (NASDAQ:MDRX) to report $0.13 EPS on May, 3 after the close.They anticipate $0.03 EPS change or 30.00% from last quarter’s $0.1 EPS. MDRX’s profit would be $23.13M giving it 23.79 P/E if the $0.13 EPS is correct. After having $0.14 EPS previously, Allscripts Healthcare Solutions, Inc.’s analysts see -7.14% EPS growth. The stock increased 1.23% or $0.15 during the last trading session, reaching $12.37. About 152,849 shares traded. Allscripts Healthcare Solutions, Inc. (NASDAQ:MDRX) has declined 6.63% since April 17, 2017 and is downtrending. It has underperformed by 18.18% the S&P500.
Tesco PLC, together with its subsidiaries, operates as a grocery retailer. The company has market cap of $31.97 billion. The firm also provides retail banking and insurance services. It has a 16.19 P/E ratio. It has activities in the United Kingdom, the Republic of Ireland, the Czech Republic, Hungary, Poland, Slovakia, Malaysia, Thailand, and internationally.
The stock increased 0.51% or $0.05125 during the last trading session, reaching $10.05125. About 4,091 shares traded. Tesco PLC (OTCMKTS:TSCDY) has 0.00% since April 17, 2017 and is . It has underperformed by 11.55% the S&P500.
Allscripts Healthcare Solutions, Inc. provides information technology and services to healthcare organizations in the United States, Canada, and internationally. The company has market cap of $2.20 billion. It offers electronic health records, connectivity, private cloud hosting, outsourcing, analytics, patient engagement, clinical decision support, and population health management solutions. It currently has negative earnings. The company??s Clinical and Financial Solutions segment provides integrated clinical software applications and financial and information solutions, which primarily include EHR-related, and financial and practice management software solutions, as well as related installation, support and maintenance, outsourcing, private cloud hosting, revenue cycle management, training, and electronic claims administration services.
Among 26 analysts covering Allscripts-Misys Healthcare (NASDAQ:MDRX), 13 have Buy rating, 1 Sell and 12 Hold. Therefore 50% are positive. Allscripts-Misys Healthcare had 68 analyst reports since August 5, 2015 according to SRatingsIntel. The rating was maintained by Jefferies with “Buy” on Friday, October 27. The stock has “Outperform” rating by RBC Capital Markets on Friday, February 19. Cantor Fitzgerald maintained it with “Buy” rating and $17.0 target in Thursday, November 2 report. Oppenheimer maintained Allscripts Healthcare Solutions, Inc. (NASDAQ:MDRX) on Friday, August 4 with “Hold” rating. JP Morgan initiated the shares of MDRX in report on Tuesday, November 17 with “Overweight” rating. The rating was maintained by Maxim Group on Tuesday, January 10 with “Buy”. The firm earned “Buy” rating on Monday, July 24 by Jefferies. JP Morgan reinitiated the stock with “Overweight” rating in Friday, October 28 report. The rating was initiated by Canaccord Genuity on Wednesday, September 16 with “Buy”. The firm earned “Buy” rating on Friday, August 4 by Maxim Group.
By1 Winifred Garcia
